New updates have been reported about FYR Bio.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
FYR Bio has appointed Barbara K. Zehentner, MBA, PhD, HCLD (ABB), as Chief Operating Officer to lead operational strategy as the company scales its extracellular vesicle-based EV-Omics platform in neuroscience and oncology. She will oversee expansion of CLIA/CAP-ready laboratory capacity, operational execution, and partnerships with biopharma, academic, and clinical customers to support broader deployment of FYR’s AI-enabled multiomic testing.
Zehentner brings more than 20 years of experience running multi-site, high-complexity laboratory operations, most recently as COO of Molecular Testing Labs and previously as Vice President of Molecular Laboratory Operations at public company Adaptive Biotechnologies. Her mandate at FYR Bio centers on building automation, quality systems, and inspection readiness to deliver reliable, scalable EV-based biomarker outputs that can support biomarker discovery, clinical studies, and translational decision-making, positioning the company for growth as demand for liquid biopsy and multiomic insights accelerates.